In an effort to provide you with timely market feedback from the 58th ASH Annual Meeting held in December 2016, OBR and MDoutlook® are pleased to share results from MDoutlook’s OncoPolls™ conducted last month immediately after the meeting. This report explores the choice between Rituxan® and Gazyva® in the front line setting for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) and the use of Rituxan and Revlimid® in the maintenance setting for mantle cell and CLL, respectively.
Institutional Setting by Attendance of Respondents
Use of anti-CD20 mAbs in the Front Line for Different B-cell Lymphomas
Awareness of Abstracts #6 & #470
General Clinical Importance of Different anti-CD20 mAbs in FL & DLBCL
Expected Impact on anti-CD20 Usage in FL & DLBCL
Use of Maintenance Strategies for Mantle Cell Lymphoma and CLL
Awareness of Abstracts #145, #229 & #230
General Clinical Importance of Maintenance Strategies for Mantle Cell Lymphoma and CLL
Expected Impact on Maintenance Usage in Mantle Cell Lymphoma and CLL
Conclusions: Immediate Impact of 2016 ASH Presentations on Clinical Practice for B-cell Lymphomas
Submitted by Dr Robert Stephan, VP, Research and Physician Society, and Dr Jan Heybroek, President MDoutlook.